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INTRODUCTION 
In patients with AIDS, cryptococcosis is the most 
common life-threatening fungal infection, having been 
described in 5-10% and in 15-30% of patients in 
western countries and in sub-Saharan Africa, respec- 
tively [1,2]. A high relapse rate (50-60%) has been 
widely documented after discontinuation of primary 
therapy [3,4]. Lifelong suppressive treatment is there- 
fore currently recommended for patients who have 
successfully completed the initial therapy. Fluconazole 
and itraconazole have so far been considered the drugs 
of choice, owing to their oral administration and lack 
of serious toxic effects [5-91. 
For the main purpose of comparing the e&cacy 
and tolerability of these drugs, we initiated in 1991 a 
prospective randomized study on maintenance therapy 
for cryptococcosis in AIDS patients with oral 300 mg/ 
daily of either fluconazole or itraconazole. The study 
was interrupted in December 1996 after the intro- 
duction of the new, potent antiretroviral drugs that have 
significantly affected the natural history of HIV-related 
infections. 
PATIENTS AND METHODS 
FromJune 1991, all consecutive AIDS patients who had 
successfully completed primary therapy, as previously 
defined [lo], for culture-proven acute cryptococcal 
meningitis or extrameningeal disseminated crypto- 
coccosis were openly randomized in 1:l proportion to 
receive either fluconazole or itraconazole as lifelong 
maintenance treatment. Informed consent was obtained 
from all patients. Both drugs were given as capsules at 
the dosage of 300 mg once a day. Patients with a history 
of intolerance to azoles were excluded. 
Cerebrospinal fluid (CSF) cultures, serum and CSF 
cryptococcal latex agglutination antigen (CLLA) test 
(Latex-Crypt0 Antigen Detection System, Immuno- 
Mycologics, Norman, OK, USA), blood cultures and 
urine cultures were performed: at enrollment, at months 
2 ,  4, and 6, and every 3 months thereafter (or earlier 
whenever a relapse was clinically suspected). 
The major endpoints were death and cryptococcosis 
relapse; additionally, adverse events requiring drug with- 
drawal were recorded. Drop-out was defined as discon- 
tinuation of therapy for more than 2 weeks, and relapse 
as the re-emergence of clinical cryptococcosis with 
positive blood or CSF culture(s). 
In case of treatment withdrawal due to adverse 
events evoked by one of the two drugs under evalua- 
tion, maintenance therapy was pursued with the other 
drug. 
Statistical analysis 
Baseline characteristics, relapse rates and side effects of 
the treatment groups were compared and analyzed with 
the chi-squared test, Fisher exact test and Mantel- 
Haenzel test, to examine differences in proportions. 
The probability of survival, based on intention-to-treat 
analysis according to the initial treatment assignment, 
was estimated until death or cryptococcosis relapse 
according to the Kaplan-Meier method, and the treat- 
ment groups were compared by the log-rank test. 
RESULTS 
The 40 patients (35 males, 5 females; mean age 34.9 
years; 36 intravenous drug users, three homosexuals 
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and one heterosexual) eligible for the study had a mean 
CD4'cell count of 50.2/mm3 (range 4-311); mean 
CLLA was 286.9 in CSF (range 0-4096) and 2249.3 in 
serum (range 8-8192). Nineteen were assigned to 
receive fluconazole, and 21 itraconazole. The two 
groups were comparable with respect to both base- 
line characteristics and total dose of amphotericin B 
administered over the duration of primary treatment 
(mean 693 mg (range 463-993 mg) and 618 mg (range 
436-1316 mg) for the fluconazole and itraconazole 
groups, respectively). Supplemental flucytosine (mean 
daily dosage 112.7 mg/kg per day for a mean of 10 
days) had been administered to 13 fluconazole and to 
18 itraconazole patients; flucytosine was not admini- 
stered in nine cases because of low white blood cell 
(WBC) (< 1000/mm3) and/or platelet (<50 OOO/mm3) 
counts. At enrollment, all patients were symptom-free. 
The median follow-up duration was 394.6 days 
(range 69-1264). 
Antiretroviral treatment was ongoing for eight 
patients in the fluconazole group and seven in the 
itraconazole group (zidovudine monotherapy in 14 
patients and zidovudine plus didanosine in one patient); 
the length of antiretroviral treatment in the two groups 
was not statistically different. 
Two drop-outs were recorded, one in each arm, 
having spontaneously interrupted therapy at days 59 and 
321, respectively, for longer than 2 weeks. Both patients 
developed a culture-proven cryptococcal relapse. 
Failure of maintenance therapy was documented in 
only one itraconazole patient, who relapsed after 101 
days of treatment, and died while on retreatment with 
amphotericin B. 
Severe adverse reactions were observed only in 
patients under itraconazole treatment (19%; P=0.06, 
Fisher exact test): gastrointestinal symptoms in two 
patients (at days 34 and 193), skin rash in one patient 
(at day 92), and acute pancreatitis (at day 614) in one 
more patient (who did not receive didanosine). These 
four patients were shifted to fluconazole, without any 
further side effects. Itraconazole had to be discontinued 
in four additional cases (19%) due to the occurrence of 
esophageal candidiasis, defined as severe thrush and 
dysphagia, which resolved after intravenous ampho- 
tericin B treatment. 
In summary, therapy discontinuation was required 
for 8 of 21 (38.1%) patients originally assigned to the 
itraconazole arm, while no patients on fluconazole 
treatment required withdrawal (P=O.O02, Fisher exact 
test). 
The causes of death among patients assigned to 
itraconazole treatment were wasting syndrome and 
AIDS dementia complex in 12 cases, disseminated 
Mycobacterium avium complex infection in two patients, 
disseminated cytomegalovirus infection in two patients, 
cerebral toxoplasmosis in one case, Kaposi's sarcoma in 
one case, and cryptococcal relapse in one case. At the 
time of the analysis, two patients of the itraconazole 
arm, but hrther shifted to fluconazole, were still alive. 
Of the patients treated with fluconazole, two were 
still alive, one was lost at follow-up at 300 days while 
still in good condition, and eight had died from wasting 
syndrome, two from cerebral toxoplasmosis, one from 
pneumonia, two from Mycobacterium avium complex 
infection, one from Staphylococcus aureus endocarditis, 
and one from disseminated cytomegalovirus infection. 
Except for the patient with cryptococcosis relapse, 
cryptococcosis was ruled out as the cause of death on 
the basis of negative mycologic assessment by blood 
culture (all cases) and CSF culture (performed in 15 
cases with central nervous system symptoms). 
Survival estimates performed on an intention-to- 
treat basis did not reveal significant differences between 
the two study drugs (Figure 1). 
DISCUSSION 
When this study was started, there was no definite 
agreement on drug of choice, dosage and duration of 
maintenance therapy for cryptococcosis in AIDS 
patients. 
Because of their proven efficacy in cryptococcosis, 
we decided to compare itraconazole and fluconazole by 
efficacy and tolerability in long-term treatment and 
oral administration; a 300-mg daily dosage was chosen 
on empirical basis. 
The efficacy and safety of the two drugs in therapy 
for cryptococcosis in AIDS patients have already 
been compared in two studies, only recently reporting 
different dosages and follow-up duration. 
Saag et al [7] compared oral fluconazole and 
itraconazole at a dosage of 200 mg/daily, in 107 patients 
during a 52-week follow-up period. The study revealed 
a significantly greater relapse rate in itraconazole- than 
in fluconazole-treated patients (24% versus 4%, respec- 
tively). Toxicity requiring drug discontinuation was 
observed in seven (6.5%) patients. 
The efficacy and safety of fluconazole in com- 
parison to itraconazole as an 8-week consolidation 
therapy following 2 initial weeks of amphotericin B 
(with or without flucytosine) were also evaluated in 
306 patients [l l] .  In this study, the proportion of 
patients who displayed a lack of clinical response was 
similar with fluconazole (32%) and itraconazole (30%). 
Fluconazole was administered as two loading doses of 
800 mgldaily, followed by maintenance with 400 mg, 
and itraconazole under a loading dose of 600 mg/daily 
for 3 days, followed by 200 mg twice daily. Toxic effects 
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Figure 1 Kaplan-Meier estimates of survival according to treatment group. Five patients were excluded: four were still alive 
at the end of the study, and one was lost to follow-up, while in good condition, at the 300th day. ......., itraconazole; -, 
fluconazole; 0, observed cases; f, excluded cases. 
requiring drug discontinuation occurred in 3.14% of 
patients and were equally distributed between fluco- 
nazole and itraconazole. 
Despite the limited number of cases, our figures 
appear to be globally comparable with those reported 
by the above-cited studies. However, some differences 
are worth mentioning. The median follow-up length 
(394.6 days) reported in our study is, to the best of our 
knowledge, the longest so far reported, and a remark- 
ably lower global relapse rate has been recorded (2.44% 
versus 14% [7] and 31% [l l ] ,  respectively). 
Although they are of equivalent efKcacy, fluconazole 
appeared to be better tolerated than itraconazole. The 
side effects requiring drug discontinuation (19% of 
itraconazole patients) might be related both to the high 
dosage given in our study and the long follow-up; drug 
withdrawal was, in fact, recorded at weeks 13, 27 and 
87 in three cases, the fourth case having been recorded 
at week 5. 
As serum levels of itraconazole were not deter- 
mined in our patients, we are unable to explain the 
occurrence of itraconazole-refractory candidiasis; this 
is possibly related to the particular pharmacokinetic 
features displayed by this drug in AIDS patients [12,13]. 
Monitoring of azole serum levels in the course of 
lifelong treatment seems, therefore, to be advisable, 
considering that the occurrence of therapeutic failure 
associated with an increased MIC of fluconazole has 
already been documented in the course of long-term 
therapy in AIDS patients [14]. 
In conclusion, both fluconazole and itraconazole, 
given as oral 300-mg capsules once daily, appeared to 
be equally and highly effective in lifelong suppressive 
therapy for cryptococcosis in AIDS patients; however, 
itraconazole may be less well tolerated, especially in 
long-term administration. 
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Ochrobactrum anthropi is a Gram-negative, motile, non- 
fermentative, oxidase- and urease-positive, aerobic 
bacillus, formerly classified as Achrornobacter species 
or CDC group Vd, that belongs to the new genus 
Ochrobactrurn [l]. The organism is widely distributed in 
soil, environmental and water sources, including anti- 
septic solutions and dialysis fluid, and it has been 
recognized as part of the normal human flora of the 
large intestine. 0. anthropi has been rarely described as 
a human pathogen. Data concerning 0. anthropi infec- 
tions are scarce and come mainly from case reports. The 
majority of the infections were community acquired, 
and several reports have emphasized how the clinical 
syndrome caused by 0. anthropi infection was closely 
linked to the underlying condition of the host. We 
report what we believe is the first case of 0. anthropi 
non-catheter-related bacteremia in a previously healthy 
man. 
A 47-year-old man was admitted to our hospital 
complaining of a 10-day hstory offever and dry cough. 
On admission, his temperature was 39OC, the blood 
pressure was 150/95 mmHg and the pulse was 9Wmin. 
Blood was drawn for cultures, and thereafter the patient 
was given intravenous imipenem (2 g/day). He was a 
truck driver, and had no prior hospitdzation and no 
underlying disease. He was well until 10 days prior to 
admission, when he experienced fever to a maximum 
of 39S°C, chills, astenia, cough and dysuria. On  
physical examination, he showed hepatomegaly and 
diminished breath sounds in both lungs. A chest X-ray 
showed probable bilateral interstitial infdtrates. Arterial 
blood gases revealed pH 7.442, PCO;? 36.5 mmHg and 
